Canada NewsWire
TORONTO, April 17, 2018
TORONTO, April 17, 2018 /CNW/ - Eric Adams, President & CEO, InMed Pharmaceuticals Inc. (IN), joined Shaun McIver, Chief Client Officer, TMX Group, to open the market. InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed Pharmaceuticals Inc. commenced trading on Toronto Stock Exchange on March 26, 2018.
SOURCE TMX Group Limited
View original content with multimedia: http://www.newswire.ca/en/releases/archive/April2018/17/c4080.html
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member